The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Statins and Breast Cancer Biomarkers
Official Title: Statins and Breast Cancer Biomarkers
Study ID: NCT00914017
Brief Summary: There is laboratory evidence that cholesterol lowering medications (statins) inhibit the growth of breast cancer cells. Clinical studies are controversial but some show that women taking statins are less likely to get breast cancer. This ongoing randomized trial compares one-year of atorvastatin (Lipitor™) or placebo for lowering mammography-defined breast density and other surrogate markers associated with breast cancer risk.
Detailed Description: This project was designed to evaluate the effect of a specific statin (atorvastatin) on several breast cancer biomarkers. One hundred women will be treated for one year with either 40 mg of atorvastatin or placebo. The primary aim of this project is to determine the effect of atorvastatin on breast density, a known risk factor for breast cancer. In addition, the affect of atorvastatin on serum biomarkers (IGF1) and tissue biomarkers (atypia and Ki67) associated with risk is being evaluated. Because of their tolerability and safety, statins have a great potential as a breast cancer preventative agent. Should this pilot study show a significant decrease in breast density and/or change in serum and tissue biomarkers in statin treated patients these data would then be used to support a large randomized trial. This is a multi-center, prospective, randomized placebo controlled clinical trial. Target enrollment is 100 women, with 50 receiving atorvastatin and 50 receiving a similar appearing placebo tablet. Eligible women must be at least 35 years old with regular menstrual cycles and a Gail Model risk of greater than 1.66% over 5 years.
Minimum Age: 35 Years
Eligible Ages: ADULT
Sex: FEMALE
Healthy Volunteers: No
University of California, San Francisco, San Francisco, California, United States
Delaware Christiana Care CCOP, Helen F. Graham Cancer Center, Newark, Delaware, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
Duke University, Durham, North Carolina, United States
Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States
Vermont Cancer Center, Burlington, Vermont, United States
Name: Marie E Wood, MD
Affiliation: University of Vermont
Role: PRINCIPAL_INVESTIGATOR